Medifast (MED) Tops Q2 EPS by 13c

Medifast (NYSE: MED) reported Q2 EPS of $1.96, $0.13 better than the analyst estimate of $1.83. Revenue for the quarter came in at $220 million versus the consensus estimate of $191.76 million.

"This has been a strong quarter for Medifast, with strong demand and engagement among OPTAVIA Coaches and Clients helping to deliver meaningful revenue growth," said Dan Chard Chief Executive Officer of Medifast. \"We have more active earning Coaches than at any point in our history, and Coach productivity is up substantially quarter-over-quarter near all-time highs. At a time when health and wellness is more important than ever to people in the United States and around the world, our service and products are clearly resonating with consumers who want to achieve lifelong transformation one healthy habit at a time."

"We have adapted well in the face of the COVID-19 pandemic, and the fundamentals of our business remain extremely positive. We are focused on our business goals, and we remain confident in our ability to deliver consistent long-term growth for our stockholders."

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Broadcom Limited (AVGO) PT Lowered to $350 at DA Davidson
• UBS Reiterates Buy Rating on Linde (LIN) as Challenges in Helium Are 'Being Managed'